RECEIVED CENTRAL FAX CENTER

APR 1 2 2007

Atty Docket No. 155 US CP04

FAX NO.: 571/273-8300

OFFICIAL COMMUNICATION FOR THE ATTENTION OF

THE U.S. PATENT AND TRADEMARK OFFICE

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents in re Application No. 09/702,216 are being facsimile transmitted to the United States Patent and Trademark Office, on the date shown below.

Documents Attached

- 1. Revocation of Power of Attorney with New Power of Attorney (1 page)
- 2. Statement Under 37 CFR 3.73(b) (1 page)

Number of pages being transmitted, including this page: 3

Dated: April 12, 2007

Tami Haskins

PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FACSIMILE AT (510) 574-1473

PDL BIOPHARMA, INC. 34801 Campus Drive Fremont, CA 94555 Telephone: 510/574-1400 Customer No.: 47470

2002

APR 1 2 2007 PTO/SB/82 (01-06) Approved for use through 12/31/2008. OMB 0851-0035 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to re-

REVOCATION OF POWER OF **ATTORNEY WITH NEW POWER OF ATTORNEY** AND

CHANGE OF CORRESPONDENCE ADDRESS

<u>spond to a collection of information unk</u>	ess it displays a valid OMB control number
Application Number	09/702,216
Filing Date	October 30, 2000
First Named Inventor	David MACK et al.
Art Unit	1634
Examiner Name	Diana B. JOHANNSEN
Attorney Docket Number	155 US CP04

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retein a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commence, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTC/SB/98 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: PDL BioPharma, Inc.	
Application No./Patent No.: 09/702,216 - 6,780,586 Filed/Issue Date: 10/30/00 - 08/24/04	
Entitled: METHODS OF DIAGNOSING BREAST CANCER	
PDL BioPharma. Inc. , a Corporation (Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)	
states that it is: 1. the assignee of the entire right, title, and Interest; or	
2. an assignee of less than the entire right, title and interest. The extent (by percentage) of its ownership interest is%	
In the patent application/patent identified above by virtue of either:	
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.	
OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:	
To: EOS Blotechnology, Inc. The document was recorded in the United States Patent and Trademark Office at Reel <u>011269</u> , Frame <u>0528</u> , or for which a copy thereof is attached.	
2. From: EOS Biotechnology, Inc. To: Protein Design Labs, Inc.	
The document was recorded in the United States Patent and Trademark Office at Reel _014787, Frame _0675, or for which a copy thereof is attached.	
3. From: Protein Design Labs, Inc. To: PDL BioPharma, Inc. The document was recorded in the United States Patent and Trademark Office at Reel 017480 , Frame 0242 , or for which a copy thereof is attached.	
Additional documents in the chain of title are listed on a supplemental sheet.	
Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]	
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee. Signature	
Cvnthia L. Shumate 510-742-2072	
Printed or Typed Name Telephone Number	
Vice President, Legal Affairs	

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.